Application of Ectoine Containing Nasal Spray and Eye Drops in Patients With Allergic Rhinitis
Launched by BITOP AG · May 5, 2014
Trial Information
Current as of May 16, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • male or female patients
- • aged 18-70 years
- • Patients with proven allergy and acute symptoms in nose and eye which are treated with Ectoin Allergy Nasal Spray and Ectoin Allergy Eye Drops or Azelastine Nasal Spray and Azelastine Eye Drops during the observational period
- Exclusion Criteria:
- • pregnancy and nursing women,
- • drug addicts and persons unable to give consent to study participation,
- • patients with intolerance against ingredients of any of the study treatments,
- • previous eye or nose surgery,
- • concomitant treatment with anti-allergic drugs, and
- • diseases which might influence the output of the study according to the physicians' judgment.
- • contra indications according to the label
About Bitop Ag
Bitop AG is a biopharmaceutical company focused on the development and commercialization of innovative therapeutic solutions for dermatological and infectious diseases. With a commitment to advancing healthcare through cutting-edge research, Bitop AG specializes in the formulation of novel compounds and the optimization of existing treatments. The company leverages its expertise in pharmacology and biotechnology to conduct rigorous clinical trials, ensuring safety and efficacy while addressing unmet medical needs. Bitop AG is dedicated to improving patient outcomes and enhancing therapeutic options through its collaborative approach and state-of-the-art technology.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Elmshorn, , Germany
Patients applied
Trial Officials
Uwe Sonnemann, MD
Principal Investigator
HNO Praxis Elmshorn
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials